Loading…

A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third‐generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers

The main objective of this phase I trial was to investigate pharmacokinetics (PKs) of olmutinib in three racial subjects. We also evaluate safety/tolerability and a population PK and pharmacogenomic analysis were performed for explorative purposes. A dose escalation study was conducted in 56 Korean,...

Full description

Saved in:
Bibliographic Details
Published in:Basic & clinical pharmacology & toxicology 2019-10, Vol.125 (4), p.370-381
Main Authors: Noh, Young Su, Yoon, Seonghae, Kim, Suk Ran, Lee, Kyung‐Tae, Jang, In‐Jin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The main objective of this phase I trial was to investigate pharmacokinetics (PKs) of olmutinib in three racial subjects. We also evaluate safety/tolerability and a population PK and pharmacogenomic analysis were performed for explorative purposes. A dose escalation study was conducted in 56 Korean, Japanese and Caucasian subjects. The food effect was assessed in the 300 mg Korean group. Individual PK parameters were calculated by non‐compartmental methods and presented by dose and race. Genotype analysis was performed using DMET® plus to identify genotypes which affect PK characteristics. A population PK model was developed to explore inter‐individual variability and to evaluate the influence of possible covariates using NONMEM®. Tmax was 2‐3 hour, regardless of race. The mean terminal half‐life ranged from 4.8 to 7.4 hour, with no significant differences between dose or racial groups. Dose‐normalized Cmax and AUClast were not significantly different between race groups. PK parameters were similar between the fasting and fed conditions. A single‐nucleotide polymorphism in the GSTM3 gene (rs4783) and a copy number variation in the GSTM1 gene were significantly related to AUC. A one‐compartment model with first‐order absorption adequately described the observed olmutinib data. Thirty adverse events were observed in 15 subjects, of which 26 events, all mild, were possibly related to olmutinib. A single oral dose of olmutinib 100‐300 mg was safe and well tolerated. PK parameters were dose‐proportional and did not differ by race. Food intake did not affect olmutinib absorption. Pharmacogenomic analysis indicated that glutathione S‐transferase might be involved in olmutinib metabolism.
ISSN:1742-7835
1742-7843
DOI:10.1111/bcpt.13262